Loading…
Corcept Therapeutics Incorporated is projected to rise to $88.03 by 2027, a +32% move from its current price of $66.65. CORT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $64.43 | $66.73 | $69.12 | +0.13% |
| May 30 | $63.58 | $66.82 | $70.22 | +0.25% |
| May 31 | $62.96 | $66.90 | $71.10 | +0.38% |
| Jun 1 | $62.44 | $66.99 | $71.86 | +0.50% |
| Jun 2 | $62.01 | $67.07 | $72.55 | +0.63% |
| Jun 3 | $61.62 | $67.16 | $73.18 | +0.76% |
| Jun 4 | $61.28 | $67.24 | $73.78 | +0.88% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $61.28 | $67.24 | $73.78 | +0.88% |
| Week 2 | $59.49 | $67.83 | $77.36 | +1.78% |
| Week 3 | $58.27 | $68.43 | $80.38 | +2.68% |
| Week 4 | $57.34 | $69.04 | $83.13 | +3.59% |
| Week 5 | $56.59 | $69.65 | $85.73 | +4.50% |
| Week 6 | $55.97 | $70.27 | $88.22 | +5.43% |
| Week 7 | $55.44 | $70.89 | $90.63 | +6.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Corcept Therapeutics Incorporated is a biopharmaceutical company that engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease.
The company was incorporated in 1998 and is headquartered in Redwood City, California.
Corcept Therapeutics Incorporated (CORT) is a healthcare company with a current price of $66.65 and a market capitalization of $7.15B. It is ranked 1092 in market position. The stock’s near-term forecast shows a neutral to bullish trajectory over time, with 2026 listing an average price of $66.65 and a 0 ROI, followed by rising averages and bullish sentiment in later years.
A major floor 51.8% below — a decisive break under it would weaken the trend.
The nearest floor, 34.1% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 22.8% above — clearing it would confirm fresh momentum.
Key CORT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CORT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $61.20 | Buy | $61.75 | Buy |
| MA 10 | $59.11 | Buy | $59.19 | Buy |
| MA 20 | $54.82 | Buy | $55.55 | Buy |
| MA 50 | $46.61 | Buy | $49.83 | Buy |
| MA 100 | $42.13 | Buy | $49.92 | Buy |
| MA 200 | $59.52 | Buy | $54.26 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 81.96 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 183.93 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.68 | Buy |
| ROC (12) | 27.49 | Buy |
| Bollinger %B (20,2) | 1.09 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 1.18 | Buy |
| Awesome (5,34) | 10.50 | Buy |
| Ultimate (7,14,28) | 85.25 | Sell |
| Momentum (10) | 15.49 | Buy |
| Aroon Osc (25) | 92.00 | Buy |
| Hull MA (9) | 63.04 | Buy |
| ADX (14) | 43.35 | Buy |
| ATR (14) | 1.57 | Info |
The 30-day technical picture remains bullish overall, with RSI14 at 80 indicating strong momentum. The stock trades above its longer-term averages, with a 50-day simple moving average of $46.61 and a 200-day simple moving average of $59.52, suggesting a constructive trend. Key near-term levels include support at $43.90 and resistance at $66.65.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $32.15 | $66.65 | $101.38 | 0% | Neutral | |
| $67.88 | $88.03 | $122.01 | +32% | Bullish | |
| $81.25 | $109.23 | $158.20 | +64% | Bullish | |
| $96.52 | $133.77 | $200.56 | +101% | Bullish | |
| $119.73 | $170.50 | $263.17 | +156% | Bullish | |
| $153.88 | $224.69 | $355.72 | +237% | Bullish | |
| $165.80 | $247.85 | $401.40 | +272% | Bullish | |
| $176.34 | $269.52 | $445.54 | +304% | Bullish | |
| $193.49 | $302.08 | $508.87 | +353% | Bullish | |
| $188.22 | $299.93 | $514.13 | +350% | Bullish | |
| $351.77 | $616.10 | $1,135.79 | +824% | Bullish | |
| $721.83 | $1,498.11 | $3,067.00 | +21.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $32.15 | $66.65 | $78.70 | +0.00% |
| June 2026 | $59.63 | $70.47 | $85.58 | +5.73% |
| July 2026 | $62.57 | $74.75 | $92.35 | +6.08% |
| August 2026 | $62.42 | $75.22 | $94.14 | +0.62% |
| September 2026 | $62.81 | $76.22 | $96.41 | +1.33% |
| October 2026 | $65.37 | $79.84 | $101.97 | +4.75% |
| November 2026 | $65.46 | $80.41 | $103.56 | +0.71% |
| December 2026 | $63.23 | $78.10 | $101.38 | -2.87% |
Click any year to see its month-by-month CORT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, CORT is projected to trade between $32.15 and $101.38, averaging $66.65 — a potential gain of 0% from today's $66.65. A consolidation phase looks the most probable path here.
Corcept Therapeutics Incorporated's 2027 outlook centres on $88.03, within a $67.88 to $122.01 range. That is up +32% on the projected 2026 average. That marks a +32% change versus current levels. Momentum favours further upside here.
By 2028, CORT could reach as high as $158.20, with a base case around $109.23 and support toward $81.25 — roughly +64% from $66.65. Buyers look set to stay in control over this stretch.
Expect CORT to range from $96.52 to $200.56 through 2029. The $133.77 average target implies a +101% move from current prices. That is up +22% on the projected 2028 average. Momentum favours further upside here.
The CORT price prediction for 2030 points to an average of $170.50 (low $119.73, high $263.17) — a potential gain of +156% on today's $66.65. Buyers look set to stay in control over this stretch.
In 2031, CORT is projected to trade between $153.88 and $355.72, averaging $224.69 — a potential gain of +237% from today's $66.65. That is up +32% on the projected 2030 average. Momentum favours further upside here.
Corcept Therapeutics Incorporated's 2032 outlook centres on $247.85, within a $165.80 to $401.40 range. That is up +10% on the projected 2031 average. That marks a +272% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, CORT could reach as high as $445.54, with a base case around $269.52 and support toward $176.34 — roughly +304% from $66.65. Momentum favours further upside here.
Expect CORT to range from $193.49 to $508.87 through 2034. The $302.08 average target implies a +353% move from current prices. That is up +12% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The CORT price prediction for 2035 points to an average of $299.93 (low $188.22, high $514.13) — a potential gain of +350% on today's $66.65. Momentum favours further upside here.
In 2040, CORT is projected to trade between $351.77 and $1,135.79, averaging $616.10 — a potential gain of +824% from today's $66.65. That is up +105% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Corcept Therapeutics Incorporated's 2050 outlook centres on $1,498.11, within a $721.83 to $3,067.00 range. That is up +143% on the projected 2040 average. That marks a +21.5x change versus current levels. Momentum favours further upside here.
Investing $1,000 in CORT today (≈ 15.003751 CORT) could be worth
$22,477.29
+$21,477.29 (+2148%) by 2050 · US Dollar
Based on the average projected CORT price of $1,498.11 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CORTwould be worth at today's price.
$1,000 invested in CORT on May 27, 2025 (≈ 13.019139 CORT) would be worth
$867.73
-$132.27 (-13.2%) today · 0.87× · US Dollar
Based on a CORT entry price of $76.81 vs. today's $66.65.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $59.06 | $1,128.51 | +12.9% |
| 1 month ago | $46.22 | $1,442.02 | +44.2% |
| 3 months ago | $35.78 | $1,862.77 | +86.3% |
| 6 months ago | $79.4 | $839.42 | -16.1% |
| 1 year ago | $76.81 | $867.73 | -13.2% |
| All time (5.0y) ago | $21.54 | $3,094.24 | +209.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CORT forecast.
Our base-case forecast reaches $130.00 around 2029.
Implied market cap at $130.00: $13.96B
The multi-year forecast shows a bullish trajectory across most years, with 2026 listed as neutral and subsequent years increasingly positive. The 2030 forecast provides an average price of $170.50 with a min of $119.73, a max of $263.17, and an ROI of 155.8, while the 2040 forecast projects an average of $616.10 with a max of $1,135.79 and an ROI of 824.4. By 2050, the average is projected at $1,498.11, the min at $721.83, the max at $3,067.00, and an ROI of 2147.7, all under bullish sentiment.
These figures point to substantial long-term upside but are estimates and not guarantees, with wider potential ranges in later years reflecting uncertainty and variability in outcomes.
Tap a question to reveal the answer.
The forecast shows an average price of $170.50 for 2030 with a min of $119.73 and a max of $263.17. The implied ROI is 155.8%, and the sentiment is BULLISH.
Forecasts indicate bullish sentiment starting in 2027, with rising averages: 2027 avg $88.03 (ROI 32.1), 2028 avg $109.23 (ROI 63.9), 2029 avg $133.77 (ROI 100.7), and 2030 avg $170.50 (ROI 155.8). The long-term view remains bullish, with higher averages and ROIs in 2040 (ROI 824.4) and 2050 (ROI 2147.7), though these are estimates and not guarantees.
Yes. The 2040 forecast max is $1,135.79, which exceeds $1,000, and the 2050 forecast max is $3,067.00.
Current price is $66.65. The 30-day range is from $52.88 to $84.00.
The 2050 average price is $1,498.11, with a minimum of $721.83 and a maximum of $3,067.00, and an ROI of 2147.7, with bullish sentiment.
Corcept Therapeutics Incorporated Community Discussion
0Share your Corcept Therapeutics Incorporated price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.